GlassScriptPhysician profile
Raul M Portillo
NPI 1265473391
$5,272.51
in general payments reported to CMS, 2019-2025
52 companies · $541 in 2025
The $541 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,628 · 2020: $731 · 2021: $343 · 2022: $399 · 2023: $897 · 2024: $733 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,101 · Education: $70.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,100.71 |
| Education | $70.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $537.32 | 2019-2025 | Opdivo |
| Amgen INC. | $458.87 | 2019-2025 | Vectibix |
| Takeda Pharmaceuticals U.S.A., INC. | $385.29 | 2019-2024 | Alunbrig, Fruzaqla |
| Genzyme Corporation | $357.30 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $311.12 | 2019-2024 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $306.10 | 2019-2025 | |
| Gilead Sciences, INC. | $230.80 | 2021-2025 | Trodelvy |
| Rigel Pharmaceuticals, INC. | $223.81 | 2020-2024 | Tavalisse, Rezlidhia |
| Astrazeneca Pharmaceuticals LP | $213.19 | 2019-2025 | Tagrisso, Lynparza |
| Janssen Biotech, INC. | $203.93 | 2019-2025 | Rybrevant |
| Regeneron Healthcare Solutions, INC. | $141.29 | 2024-2025 | Libtayo |
| Genentech USA, INC. | $141.09 | 2019 | |
| Caris Mpi, INC. | $137.41 | 2025 | Mi Cancer Seek |
| Immunogen, INC. | $124.99 | 2023 | Elahere |
| Genmab U.S., INC. | $124.99 | 2024 | Epkinly |
Show all 50 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raul Portillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.